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Abstract
Rheumatoid arthritis (RA) is characterised by chronic synovial joint inflammation. Treatment has been revolutionised by
tumour necrosis factor alpha inhibitors (TNFi) but each available drug shows a significant non-response rate. We conducted
a genome-wide association study of 1752 UK RA TNFi-treated patients to identify predictors of change in the Disease
Activity Score 28 (DAS28) and subcomponents over 3–6 months. The rs7195994 variant at the FTO gene locus was
associated with infliximab response when looking at a change in the swollen joint count (SJC28) subcomponent (p= 9.74 ×
10−9). Capture Hi-C data show chromatin interactions in GM12878 cells between rs2540767, in high linkage disequilibrium
with rs7195994 (R2= 0.9) and IRX3, a neighbouring gene of FTO. IRX3 encodes a transcription factor involved in adipocyte
remodelling and is regarded as the obesity gene at the FTO locus. Importantly, the rs7195994 association remained
significantly associated following adjustment for BMI. In addition, using capture Hi-C data we showed interactions between
TNFi-response associated variants and 16 RA susceptibility variants.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder
affecting around 1% of the United Kingdom (UK) popula-
tion [1], which leads to synovial joint inflammation and
joint damage. Tumour necrosis factor (TNF) is a pro-
inflammatory cytokine essential for immunity to infections;
however, its dysregulation is important in the pathogenesis
of RA and many other chronic inflammatory diseases [2].
It is primarily, but not exclusively, produced by activated
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macrophages and exerts its function through binding to its
cognate receptors: TNFR1 and TNFR2 [3]. There are a
number of TNF inhibitor (TNFi) biologics and biosimilars
licensed for treatment of RA within the UK: Infliximab
(Remicade, biosimilars: Remsima and Inflectra), adalimu-
mab (Humira), certolizumab pegol (Cimzia), and golimu-
mab (Simponi) are antibodies or fragments of antibodies
that are targeted towards the TNF, whilst etanercept
(Enbrel, biosimilar: Benapali) comprises two TNFR2 extra-
cellular domains fused to the IgG1 Fc.
Response to TNFi treatment varies between individuals,
with as many as 30–40% showing no clinical improvement
[4]. Given the expense of these drugs (around 5000–10,000
GBP per patient per year in the UK) and the potential
for detriment to non-responding patients, the identification
of predictors of response from pre-treatment (baseline)
characteristics would be of great clinical, societal and
economic benefit. The importance of this question moti-
vated the formation of the UK MAximizing Therapeutic
Utility in RA (MATURA) consortium [5], which has the
wider remit of using blood-based biomarkers and synovial
pathobiology to inform the stratification of all stages of
RA treatment.
Genetic variants are stable characteristics that can be
easily measured on a genome-wide scale. Previous genome-
wide association studies (GWASs) of response to TNFi
agents in RA have identified the CD84 [6] and PDE3A-
SLCO1C1 [7] loci as the strongest candidates but reprodu-
cibility has been an issue [8] and recent studies have
questioned the utility of studying genetic variation in rela-
tion to response to TNFi in RA [9]. However, previous
studies have been limited by small sample sizes, different
population sub-groups, and inconsistent measures of
response and follow-up times.
In the current study, we present a large GWAS of TNFi
response in UK RA patient samples, which were all col-
lected using the same study protocol and analysed using not
only the composite measure of response (change in disease
activity score in 28 joints (DAS28)) but also the sub-
component of the score.
Methods
Patients
The British Society for Rheumatology Biologics Register
for Rheumatoid Arthritis (BSRBR-RA) was established
with the aim of assessing the safety of biologic agents in the
treatment of RA and has collected detailed clinical and
response data (www.bsrbr.org). Collaborations have been
established between some of the larger referring centres to
form the Biologics in Rheumatoid Arthritis Genetics and
Genomics Study Syndicate (BRAGGSS; www.braggss.co.
uk), which collects blood samples from biologic treated RA
patients for DNA, RNA and cellular studies. Contributing
patients provide written informed consent, and the
BRAGGSS study is ethically approved (COREC 04/Q1403/
37).
For the current study, clinical measurements collected
included swollen 28-joint count (SJC28), tender 28-joint
count (TJC28), erythrocyte sedimentation rate (ESR) and
patient global health assessment (PGA), as measured by
visual analogue scale (VAS). Measurements of these were
taken at baseline and again at follow-up (between 3 and
6 months).
Patients were selected for genotyping if they were cur-
rently receiving or about to begin receiving treatment with a
TNFi. Patients were excluded if they stopped treatment
within the first 6 months for reasons other than lack of
efficacy. Of the 1770 patients available for this study:
76.8% were female, 92.8% were receiving their first bio-
logic treatment, and other baseline characteristics are shown
in Table 1.
Four component disease activity scores (DAS28-ESR)
(0.56(√TJC28)+ 0.28(√SJC28)+ 0.70(ln(ESR))+ 0.014 ×
PGA) were calculated for each individual at baseline and
follow-up. Where this was not possible, due to missing PGA
in a small number of cases, a three component DAS28 was
calculated as follows: [0.56(√TJC28)+ 0.28(√SJC28)+
0.70(ln(ESR))] × 1.08+ 0.16.
Genotyping
Genotype data from 1770 samples was generated from
several Affymetrix and Illumina arrays: Affymetrix Gene-
Chip Mapping 500K Array Set (presented previously [10]),
Affymetrix Genome-Wide Human SNP Array 6.0, Illumina
HumanHap550/Illumina HumanHap650, Illumina Omni-
Express, and Illumina HumanCoreExome (Supplementary
Table 1). Standard QC was conducted on each individual
array: SNPs and samples were excluded if there was >2%
missing data, and SNPs with MAF < 0.01 and Hardy
Table 1 Baseline patient characteristics
Baseline measure Mean (standard deviation) Range
Age 56.9 years (11.36) 19.6–85.3
Disease duration 12.4 years (9.92) 0.09–54.8
DAS28 score 6.35 (0.97) 1.72–9.2
SJC28 10.59 (6.12) 0–28
TJC28 15.94 (7.27) 0–28
ESR 37.19 mm/h (28.16) 0.18–137
PGA 71.7 VAS measure (18.87) 0–100
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Weinberg Equilibrium (HWE) p < 1 × 10−4 were also
excluded.
Ideally for imputation, the intersection of SNPs from
across all arrays would be used but this yielded < 10,000
SNPs. Therefore, the arrays were grouped as follows,
showing the number of SNPs available for imputation:
Affymetrix group (272 006 SNPs), IlluminaHumanHap
group (460 812 SNPs) and the Illumina Omni-HumanCore
group (204 894 SNPs).
The three groups were then imputed separately to
the Haplotype Reference Consortium (release 1.1) [11] using
the Sanger Imputation Service (https://imputation.sanger.ac.
uk/). The pre-phasing was performed using SHAPEIT2 [12]
and imputation using the PBWT algorithm [13].
Imputed files were filtered to exclude variants with an
INFO score <0.8. The files were then subset to include only
the variants common to all three groups (9,814,288 SNPs).
GCTA [14] was used to conduct principal component
analysis (PCA) and generate a genetic relationship matrix
(GRM). These were used to exclude samples of non-
Caucasian ethnicity and samples that showed genetic
relatedness (GRM cut-off 0.05).
Statistical analyses
Genotype data from the three separate imputation groups
were analysed for change in outcome from baseline to
follow-up (baseline measure minus 3–6 month follow-up
measure, where the baseline measure is taken before the
start of TNFi treatment) of DAS28 (calculated using ESR),
SJC28, TJC28, ESR and PGA. These will be termed
ΔDAS28-ESR, ΔSJC28, ΔTJC28, ΔESR and ΔPGA,
respectively (the raw distributions of these measures are
shown in Supplementary Figure 1).
First, a combined analysis including all TNFi was per-
formed, followed by the three largest drug groups inde-
pendently: adalimumab (Humira), etanercept (Enbrel), and
infliximab (Remicade).
SNPTEST v2.5.2 [15] was used to implement the
linear regression of these measures assuming an additive
genetic model. All measures were mean-centred and
scaled to have a variance of 1 within each group before
the linear regression. The following covariates were
used in the linear regression: first three principal compo-
nents, the baseline measure (DAS28-ESR, SJC28, TJC28,
ESR or PGA at commencement of treatment—also mean-
centred and scaled to have a variance of 1), sex, concurrent
disease-modifying anti-rheumatic drugs (DMARDs), and
imputation group (described above). Imputed genotype
uncertainty was dealt with using a missing data likelihood
score test (“−score” option). Only SNPs with a minor
allele frequency (MAF) ≥ 0.05 in each group were con-
sidered for the primary analysis. Low-frequency SNPs
(MAF ≥ 0.01 < 0.05) were considered in a secondary ana-
lysis. SNP associations at the <5 × 10−5 p-value threshold
were considered suggestive of association.
Chromosome conformation capture data
Chromosome conformation capture technology (Capture
Hi-C) data from various sources [16–18] were used
to investigate chromatin interactions between associated
variants and distant chromosomal regions. This technology
can help in the selection of candidate genes and provide
mechanistic insights at associated loci, as has been
demonstrated previously [17, 19]. Capture HiC Plotter
(CHiCP) was used for data visualisation [20].
Heritability estimation
We estimated the heritability of response to TNFi, as
measured by the change in DAS28 components between
baseline and 6-month follow-up: Δlog(ESR), Δ√SJC28,
Δ√TJC28, ΔPGA. To make each response measure as
homogeneous as possible, we excluded samples that
were only followed-up at 3 months. Each outcome was
adjusted for: first ten principal components, baseline mea-
sure, sex, concurrent DMARDs, genotyping array, and
study. Heritability was estimated using the rank-
transformed residuals from linear regression of each out-
come on the covariates.
We estimated heritability using GCTA [14] and a
Bayesian hierarchical model. The asymptotic large-sample
approximations underlying the REML estimation used in
GCTA are unlikely to hold with the modest sample size
available for this study [21]. For this reason, in addition
to GCTA, we used a fully Bayesian method that does
not depend on large-sample approximations and returns
the posterior distribution of heritability. The Bayesian
model was implemented using JAGS (http://mcmc-jags.
sourceforge.net) and its R interface package rjags. Inference
was performed using Markov chain Monte Carlo sampling
(see Supplementary Information 1 for details).
Results
A total of 1752 samples passed quality control, with the
maximum number available for analysis depending on
the trait: 1723 for ΔSJC28/ΔTJC28, 1709 for ΔPGA, 1569
for ΔDAS28 (based on ESR), and 1514 for ΔESR
(Table 2). There are fewer ΔESR than ΔDAS28-ESR as
the calculated DAS28-ESR was sometimes available from
clinical notes without the individual component values.
The study had >80% power to detect a difference in the
DAS28 of ≥0.6 units (a clinically meaningful change
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as defined by EULAR response criteria) for allele fre-
quencies of ≥5%.
Across all drugs and outcomes, studying variants with a
MAF > 5%, five loci had p < 1 × 10−5, with one, rs7195994
mapping to the FTO gene locus, surpassing genome-wide
significance (p < 5 × 10−8) (Table 3). Lower frequency
variants are presented in Supplementary Table 2. For all of
the SNPs with a MAF > 5%, there was evidence of asso-
ciation (p < 0.01) at the same SNP in at least one other
outcome and/or TNFi agent (Supplementary Table 3). The
Quantile–Quantile (QQ) plots for each analysis are shown
in Supplementary Figure 2.
All TNFi combined
One variant, rs2187874 intronic in the ZNF595 / ZNF721
genes (Supplementary Figure 3a) was associated with
ΔTJC28 phenotype, (p= 7 × 10−8). The variant has chro-
matin interactions in the GM12878 data [18] with PIGG
and ZNF721 genes (Supplementary Figure 3b) but neither
gene is an obvious candidate and findings will require
replication.
Infliximab
rs7195994 on chromosome 16, intronic in the FTO gene,
was associated with response to infliximab when analysing
ΔSJC28 (p= 9.74 × 10−9) (Supplementary Figure 4a).
FTO encodes a 2-Oxoglutarate–Dependent Nucleic Acid
Demethylase and is associated with obesity [22] and Body
Mass Index (BMI) [23]. rs7195994 is in LD with rs2540767
(r2= 0.9), which shows chromatin interaction with the IRX3
gene [18] (Supplementary Figure 4b), which some studies
have suggested is one of the causal genes for obesity/BMI
at the FTO locus [24]. However, the SNP presented
here remains associated with response to infliximab at the
genome-wide level even after adjusting for BMI. Further-
more, there was no association in these samples using
a linear regression (including the same covariates as the
GWAS) between ΔSJC28 and a weighted genetic risk
score (wGRS) calculated from the effect sizes for SNPs
associated with both BMI and waist circumference in two
studies [25, 26].
A variant, rs11599217, showing chromosome interac-
tions with the DOCK1 gene was significantly associated
with ΔTJC28 (p= 7.27 × 10−8) (Supplementary Figure 5).
DOCK1 (also called Dock180) functions with the ELMO1
protein to regulate the actin cytoskeleton during phagocy-
tosis (through the small GTPase Rac) [27].
Adalimumab
The most significant association in the adalimumab treated
subgroup was for the rs10739537 variant on chromosome
Table 3 Association analysis results (p < 1x 10−7) for variants with MAF ≥ 5 %
Pheno TNFi Gene region SNP Chr BP A1 A2 Genotype
counts
MAF P Beta SE
SJC28 Infliximab intronic FTO rs7195994 16 54060205 G A 363/68/3 0.085 9.74E-09 −0.48 0.08
SJC28 Adalimumab intergenic BRINP1/
LINC01613
rs10739537 9 122188604 G T 70/275/206 0.377 9.11E-08 −0.21 0.04
PGA Etanercept intergenic MMP20/MMP27 rs948138 11 102501665 G A 132/292/191 0.452 7.62E-08 0.25 0.05
TJC28 Infliximab intergenic C10orf90/
DOCK1
rs11599217 10 128566964 G T 128/210/96 0.463 7.27E-08 −0.29 0.05
TJC28 All intronic ZNF595,ZNF718 rs2187874 4 82321 G T 1279/397/47 0.142 7.00E-08 −0.19 0.04
Table 2 Sample numbers
post-QC
TNFi Phenotype, n (imputation group 1 / 2 / 3)
ΔDAS28 ΔESR ΔSJC28 ΔTJC28 ΔPGA
Adalimumab 500 (171/284/45) 487
(162/282/43)
551 (169/339/43) 551 (169/339/43) 549 (167/339/43)
Etanercept 564
(309/243/12)
549
(297/240/12)
619 (304/303/12) 619 (304/303/12) 615 (301/302/12)
Infliximab 441
(331/56/54)
414
(310/53/51)
434 (319/63/52) 434 (319/63/52) 426 (313/62/51)
Other 64 (0/64/0) 64 (0/64/0) 119 (0/119/0) 119 (0/119/0) 119 (0/119/0)
Total 1569
(811/647/111)
1514
(769/639/
106)
1723
(792/824/107)
1723
(792/824/107)
1709
(781/822/106)
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9 and ΔSJC28 phenotype (p= 9.11 × 10−8). The variant is
located upstream of the BRINP1 (also called DBC1) gene
(Supplementary Figure 6). Interestingly, DBC1 is an
essential subunit of the FOXP3 complex in human CD4+
regulatory T-cells (Tregs) [28] and these cells are thought to
be the major driver of RA susceptibility.
Etanercept
The only locus with p < 1 × 10−7 when analysing the
ΔPGA phenotype across all drugs was in etanercept.
rs948138 (p= 7.62 × 10−8) (Supplementary Figure 7a),
shows chromatin interactions in a number of cell types
(Macrophages, Naive B-cells, Naive CD4+, Naive CD8+
and Activated CD4+) with the promoter of BIRC2 [16]
(Supplementary Figure 7b).
Low frequency variants
There were 14 variants with a MAF < 5% but ≥1% that
were associated p < 1 × 10−7 (Supplementary Table 2).
However, these were considered separately due to both
limited power and difficultly, despite INFO scores >0.8,
in ascertaining accuracy. To add potential support to such
SNPs, we looked for evidence of association (p < 0.01)
in other outcomes and other TNFi agents (Supplementary
Table 3). The only SNP without such support was
rs34619498, intronic in EMCN.
The SNP in RAD51B is of particular note given that this
locus is associated with RA susceptibility. Interestingly,
using in-house capture-HiC data [17] from GM12878 cells,
we can show interaction between the RAD51B SNPs asso-
ciated with treatment response (namely rs193127299 in
perfect LD with rs140825531) and the RA susceptibility
SNPs (Supplementary Figure 8).
RA susceptibility loci
Given the finding that RAD51B treatment response SNPs
have chromatin interactions with RA susceptibility SNPs
in the same region, we used in-house Capture-HiC data
from GM12878 and Jurkat cell lines to look at all variants
p < 1 × 10−4 across all analyses for any further links. We
found chromatin interactions between treatment response
SNPs and a further 15 loci associated with RA susceptibility
(Supplementary Table 4).
Heritability estimation
The estimated heritability for each DAS28 component is
presented in Table 4. We report the 90% credible interval,
the posterior mean and the standard deviation from the
posterior distribution of heritability under the Bayesian
model, and the REML estimate of heritability and its stan-
dard error from GCTA.
TNFi response based on 6-month change in ESR and 6-
month change in SJC28 is heritable, with 90% of the pos-
terior probability lying between 0.09–0.81 for ESR
response and 0.08–0.69 for SJC28 response, clearly
excluding 0. The posterior mean estimates are 0.49 and
0.40, for ESR response and SJC28 response, respectively.
On the contrary, for TJC28 and PGA response there is
no evidence of non-zero heritability, with 0 being inside
the 90% credible interval. Furthermore, the posterior
mode for TJC28 and PGA response is at 0, while for ESR
and SJC28 response the posterior mode is at 0.53 and
0.36, respectively (Supplementary Figure 9). Results using
non-transformed residuals and different GRM constructions
are consistent with the results in Table 4 (Supplementary
Figure 10).
Discussion
In a large study of TNFi response in the UK, we have found
no variants predictive of change in DAS28 score over the
first 3–6 months of treatment. Nonetheless, stratified ana-
lysis has revealed several potentially interesting associations
worthy of further investigation. First, we found that a var-
iant in the FTO gene, robustly associated with BMI in
several studies, was significantly associated with improve-
ment in the SJC28 in infliximab-treated patients. The
association is of particular interest as high BMI was shown
to be a significant predictor of lower drug levels in both
adalimumab and etanercept treated patients in BRAGGSS
[29] and postulated to contribute to non-response through
lack of bioavailability and from the increased inflammatory
effect of adipose tissue [30]. A conclusion of the study in
Table 4 Heritability analysis
results
Phenotype 90% Credible Interval
Bayesian model
Posterior Mean
Bayesian model
REML Estimate (se)
GCTA
Number of
samplesa
Δlog(ESR) 0.09–0.81 0.49 0.48 (0.23) 1463
Δ√SJC28 0.08–0.69 0.40 0.39 (0.21) 1637
Δ√TJC28 0.00–0.33 0.16 0.00 (0.20) 1637
ΔPGA 0.00–0.33 0.16 0.00 (0.21) 1626
aAfter excluding samples without 6-month follow-up from the 1752 samples that passed the GWAS QC
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BRAGGSS [29] was to potentially switch high BMI
patients to TNFi agents that account for patient weight.
Infliximab is one such drug and is administered by intra-
venous infusion. Therefore, the finding here of FTO in
infliximab treated patients, and the results after controlling
for BMI, suggest an association independent of BMI. Fur-
ther replication of this signal will be required and it is
possible that other measures of obesity, such as hip/waist
ratio, may be required to disentangle the effect.
The association of BRINP1 gene locus variant with
ΔSJC28 in adalimumab treated patients potentially links
TNFi response to immune regulation. BRINP1 (DBC1)
downregulation in a mouse model prevents FOXP3 degra-
dation, maintaining CD4+ Treg function under TNF-α and
IL-6 inflammatory stimuli [28]. Treg function is known to
be impaired in RA [31] so it could be postulated that this
variant is driving a positive response to adalimumab
through a down-regulation of DBC1, thereby boosting Treg
function. This supports the finding that adalimumab, but not
etanercept, can expand functional Treg cells in RA [32].
It is interesting to note that interactions between TNF-
response associated variants are observed with 16 RA sus-
ceptibility variants, including the RAD51B, TNFAIP3, and
PTPRC genes. The latter has now been implicated as a
predictor of TNFi response in multiple studies [33–35],
whilst other studies have reported no association [36, 37].
However, it should be noted that the fragment sizes for the
Capture Hi-C experiments are large (~4 kb) so it is possible
that the apparent enrichment is an artefact. Further work,
which might include the targeting of the treatment response
SNPs and repeating the capture Hi-C experiments, will be
required to ascertain the mechanisms underlying these
interactions.
In the current study it is interesting to note that our most
significant findings were when subcomponents of the
DAS28 score were analysed separately, particularly the
change in SJC28. We have previously argued that genetic
changes are likely to affect a biological process, which are
more likely to be captured by objective rather than sub-
jective measures. This is supported by the heritability ana-
lysis results where we demonstrated that TNFi response as
measured by 6-month change in the objective components
of the DAS28 (ESR and SJC28) are heritable. The low
evidence for heritability of the subjective DAS28 compo-
nents (TJC28 and PGA) is in line with other studies that
have found that these components of the score do not cor-
relate with synovitis assessed by magnetic resonance ima-
ging [38]. This is not to suggest patient attitudes to
treatment and their well-being should be ignored, as this is
likely to impact adherence. Furthermore, we cannot exclude
a heritable component to TJC28 and PGA, albeit smaller
than that of SJC28 and ESR, that the study was under-
powered to detect. Indeed, a previous study in a Dutch
population reported a higher heritability for TJC28 com-
pared with the current study [39].
Whilst the study has several strengths including recruit-
ment from a single country, a unified study design and large
sample size, there are also several limitations that should be
recognised. First, we have previously reported in a study of
748 patients, from the same BRAGGSS cohort, that 27% of
patients self-reported non-adherence to TNFi therapy in the
first 6 months of treatment [40]. Therefore, as with all
treatment response studies, adherence to treatment is a
potential confounder, which we have not been able to
account for in the current work because the data were not
available for all patients. This is less of a problem for
infliximab, where administration is by intravenous infusion
in a clinical setting.
Second, we have also reported previously that immu-
nogenicity, the development of antidrug antibodies
(ADAbs), towards TNFi agents is also a potential con-
founder. In a cohort of 115 BRAGGSS patients treated with
certolizumab pegol, ADAbs were detected in 37% of
patients by 12 months of treatment [41]. In a similar study,
the figure for adalimumab was 24.8%, but in etanercept no
ADAbs were detected [29]. Work is already underway to
test ADAbs and drug levels in serum samples from this
cohort, which will inform future research, but it was not
possible to adjust for this in the current analysis.
The lack of strong genetic effects in our GWAS suggests
that anti-TNF response is highly polygenic with many small
effects. The sample size required to detect associations with
SNPs, or to construct a useful genetic predictor from
associations detected in a GWAS, may be larger than is
feasible for studies of drug response. Alternative approaches
to constructing genetic predictors, such as genetic scores for
related traits or biomarkers using summary results from
large GWAS, may have better utility.
In conclusion, we have demonstrated that TNFi response
as measured by 6-month change in the objective compo-
nents of the DAS28 (ESR and SJC28) is heritable, and thus
genetic stratification of patients could improve targeting of
treatment. We have found a number of potentially inter-
esting variants associated with response to different TNFi
agents. Many of these variants have demonstrated chro-
matin interactions to strong candidate genes in relevant cell
types. Future studies will be necessary to determine the
function of these SNPs but such interactions could suggest a
potential regulatory function.
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